Prospective crossover clinical trial comparing transdermal with oral phenobarbital administration in epileptic cats

Abstract

Objectives The aim of this study was to compare serum phenobarbital concentrations, adverse events and client satisfaction during 14 weeks of transdermal vs oral phenobarbital administration to epileptic cats. Methods This was a prospective, fixed-order, crossover pilot study. Nine client-owned cats with presumptive or diagnosed idiopathic epilepsy were enrolled. Oral phenobarbital (PO-PB) was administered for weeks 1–14 (median starting dosage of 3.8 mg/kg [2.0–5.4 mg/kg/day] q12h); transdermal phenobarbital (TD-PB) was administered for weeks 14–28 (median starting dosage 18.8 mg/kg/day [17.6–24.0 mg/kg/day] q12h). Serum phenobarbital concentrations (S-PB) were measured at weeks 2, 14, 16 and 28. Client satisfaction questionnaires and biochemistry were evaluated at 14 and 28 weeks. Results Median S-PB concentrations during oral administration were 21 µg/ml (observed range 11–40 µg/ml) at week 2 and 22 µg/ml (8–35 µg/ml) at week 14, and at the higher TD dosage were 18 µg/ml (0–42 µg/ml) at week 16 and 17 µg/ml (7–50 µg/ml) at week 28. Phenobarbital concentrations were significantly correlated with PO dosage at week 2 (r = 0.75, P = 0.03) but not at weeks 16 and 28. Significantly more dose adjustments were needed during the TD phase (P = 0.03), but 6/9 owners (67%) still preferred TD to PO administration. Adverse effects were mild and comparable in both groups. Conclusions and relevance Therapeutic S-PB concentrations were achievable in some cats using TD-PB at 18 mg/kg/day q12h. Poor correlation between TD dosage and S-PB concentrations was observed and more dosage adjustments were required during TD administration. These findings necessitate close therapeutic drug monitoring if TD-PB is prescribed.